Related Experiment Video
Updated: Jul 6, 2026
08:09
Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
[Responsive changes to MPTP in rats with DAT inhibited by antisense oligonucleotides]
Yan-ming Xu1, En-xiang Tao, Xiao-jun Ding
1Department of Neurology, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041 P. R. China. neuroxym@163.net
Summary
Antisense oligonucleotides (ODN) effectively inhibit dopamine transporter (DAT) expression in rats. This inhibition reduced the rats' response to MPTP, suggesting a potential therapeutic strategy for neurodegenerative conditions.
Area of Science:
- Neuroscience
- Molecular Biology
- Pharmacology
Context:
- Dopamine transporter (DAT) plays a crucial role in regulating dopaminergic neurotransmission.
- Dysfunction of the dopaminergic system is implicated in various neurological disorders, including Parkinson's disease.
- 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a neurotoxin used to induce Parkinsonism in animal models.
Purpose:
- To investigate the inhibitory effect of antisense oligonucleotides (ODN) on dopamine transporter (DAT) in rats.
- To evaluate the impact of DAT inhibition on the rats' response to MPTP exposure.
- To assess the neuroprotective potential of DAT inhibition.
Summary:
- Antisense ODN were administered to the substantia nigra compacta in rats, followed by MPTP injection.
- Immunohistochemistry revealed significantly lower DAT expression in the antisense ODN group compared to control groups.
- Rats treated with antisense ODN exhibited reduced behavioral responses to apomorphine and decreased dopamine cell apoptosis.
Impact:
- Antisense ODN effectively inhibit DAT expression in vivo.
- DAT inhibition mitigates the neurotoxic effects of MPTP, offering a potential therapeutic avenue.
- This study provides evidence for targeting DAT as a strategy to protect dopaminergic neurons.
